Outcome of COVID-19 Infection in Vaccinated Patients in Kirkuk City

Abstract

At 2019 an epidemic of viral infection was declared by the WHO, and the virus causing this epidemic was identified and known as (SARS-CoV-2) severe acute respiratory syndrome coronavirus 2. To assess the outcome and severity of infection with COVID-19 virus after been vaccinated with different types of Covid-19 vaccines though various clinical and lab investigations. One thousand patients infected with covid-19 was collected from Azadi teaching hospital and Shifa-14 hospital at Kirkuk city; from 1^st August to 31^st January 2022, all of them were vaccinated by two doses, 400 patients with Sinopharm vaccine, 400 with Pfizer–BioNTech vaccine and 200 with AstraZeneca vaccine. Laboratory investigations like CBC, CRP, serum ferritin, serum LDH and d-dimer, chest CT were done for the symptomatic patients to assess their severity. The study found that from 400 COVID-19 patients who were vaccinated with two doses of Sinopharm vaccine, 200 patients had just mild symptoms, 125 had moderate symptoms, 75 patients complained from severe symptoms requiring hospital admission and 10 of them had passed. 400 patients were vaccinated with two doses of Pfizer vaccine, 300 patients had just mild symptoms, 70 patients moderate and 30 patients complained from severe illness required hospital admission and 3 patients passed. 200 patients were vaccinated with two doses of AstraZeneca vaccine, 120 patients had just mild symptoms, 60 patients moderate and 20 patients complained from severe illness required hospital admission and 5 patients passed. It was concluded that majority of vaccinated individuals suffered just from mild symptoms.

The Aim of the study is to assess the outcome of COVID-19 infection in vaccinated patients (Sinopharm, AstraZeneca, and Biotech-Pfizer vaccine) in Kirkuk city, the mortality, mild, moderate and severe cases.